Suppr超能文献

基因突变特征与胃肠道癌的生存相关。

Mutational Signatures Associate With Survival in Gastrointestinal Carcinomas.

机构信息

Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, Helsinki, Finland;

Department of Pathology, Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland.

出版信息

Cancer Genomics Proteomics. 2022 Sep-Oct;19(5):556-569. doi: 10.21873/cgp.20340.

Abstract

BACKGROUND/AIM: Mutational signatures reflect common patterns based on the counts of mutations and their sequence context. The prognostic value of these signatures, mirroring various carcinogenetic processes of cancers, are unexplored in gastrointestinal cancers. Our aim was to evaluate possible prognostic relevance of mutational signatures in gastrointestinal carcinomas after adjusting with the traditional prognostic factors.

MATERIALS AND METHODS

We used publicly available data from The Cancer Genome Atlas and Pan-Cancer Analysis of Whole Genomes to evaluate the associations between survival endpoints and activity of mutational signatures in seven types of gastrointestinal cancers.

RESULTS

Most strikingly, the high activity of age-related single-base substitution 5 (SBS5) and SBS40 signatures were in rectal adenocarcinomas associated with both improved overall survival (OS) [for SBS5 hazard ratio (HR) 0.130; 95% CI=0.03-0.56, for SBS40 HR=0.072; 95% CI=0.012-0.44, respectively] and similarly also to rectal cancer-specific survival. In patients with left-sided (but not right-sided) colon adenocarcinoma, the high activity of SBS2 signatures, formed due to APOBEC activity, predicted shortened OS. In pancreatic cancer, the high activity of SBS10b, caused by polymerase epsilon exonuclease proofreading defects, was associated both with longer OS (HR=0.44; 95% CI=0.205-0.96) and pancreatic cancer-specific survival (HR=0.32; 95% CI=0.112-0.91).

CONCLUSION

Several mutational signatures seem to have clinically meaningful, cancer-specific associations with prognosis among gastrointestinal cancers.

摘要

背景/目的:突变特征反映了基于突变数量及其序列背景的常见模式。这些特征的预后价值反映了癌症的各种致癌过程,但在胃肠道癌症中尚未得到探索。我们的目的是在调整传统预后因素后,评估突变特征在胃肠道癌中的可能预后相关性。

材料和方法

我们使用来自癌症基因组图谱和全基因组泛癌分析的公开可用数据,评估了七种胃肠道癌的生存终点与突变特征活性之间的关联。

结果

最引人注目的是,直肠腺癌中与整体生存(OS)改善相关的年龄相关单碱基替换 5(SBS5)和 SBS40 特征的高活性[对于 SBS5 危险比(HR)为 0.130;95%置信区间(CI)为 0.03-0.56,对于 SBS40 HR 为 0.072;95%CI=0.012-0.44],同样与直肠癌特异性生存相关。在左侧(而非右侧)结肠癌患者中,APOBEC 活性引起的 SBS2 特征的高活性预测 OS 缩短。在胰腺癌中,由于聚合酶 epsilon 外切核酸酶校对缺陷引起的 SBS10b 高活性与 OS 延长(HR=0.44;95%CI=0.205-0.96)和胰腺癌特异性生存(HR=0.32;95%CI=0.112-0.91)均相关。

结论

几种突变特征似乎与胃肠道癌的预后具有癌症特异性的临床意义关联。

相似文献

6
Mutational signatures in colon cancer.结肠癌中的突变特征。
BMC Res Notes. 2019 Dec 3;12(1):788. doi: 10.1186/s13104-019-4820-0.

本文引用的文献

2
A body map of somatic mutagenesis in morphologically normal human tissues.形态正常人体组织中的躯体突变体图谱。
Nature. 2021 Sep;597(7876):398-403. doi: 10.1038/s41586-021-03836-1. Epub 2021 Aug 25.
3
The mutational landscape of human somatic and germline cells.人类体细胞和生殖细胞的突变景观。
Nature. 2021 Sep;597(7876):381-386. doi: 10.1038/s41586-021-03822-7. Epub 2021 Aug 25.
4
Mutational signatures: emerging concepts, caveats and clinical applications.突变特征:新兴概念、注意事项与临床应用
Nat Rev Cancer. 2021 Oct;21(10):619-637. doi: 10.1038/s41568-021-00377-7. Epub 2021 Jul 27.
8
BRAF Mutated Colorectal Cancer: New Treatment Approaches.BRAF 突变型结直肠癌:新的治疗方法
Cancers (Basel). 2020 Jun 14;12(6):1571. doi: 10.3390/cancers12061571.
9
Challenges in the treatment of gastric cancer in the older patient.老年胃癌患者的治疗挑战。
Cancer Treat Rev. 2020 Apr;85:101980. doi: 10.1016/j.ctrv.2020.101980. Epub 2020 Feb 10.
10
The repertoire of mutational signatures in human cancer.人类癌症中的突变特征谱。
Nature. 2020 Feb;578(7793):94-101. doi: 10.1038/s41586-020-1943-3. Epub 2020 Feb 5.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验